Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First

IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a […]


1 w.
Science
ID: -1915512482430306993


Similar News expand_more


Science
Science
Science
Science
Science
Science
Science
Science
Science
Technology
Science
Science
Science
Technology
Science
Technology
Technology
Technology
Technology
Technology
Technology
Economics
Science
Science
Technology
Technology
Science
Science
Technology
Technology
Science
Science
Economics
Science
Technology
Technology
Economics
Science
Science
Economics
Technology
Technology
Technology
Space
Science
Technology
Science
Science
Education
Add Watch Country

arrow_drop_down